KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Shares Outstanding (2017 - 2025)

Twist Bioscience (TWST) has disclosed Shares Outstanding for 9 consecutive years, with $61.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.84% to $61.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.3 million through Dec 2025, up 2.84% year-over-year, with the annual reading at $60.6 million for FY2025, 2.98% up from the prior year.
  • Shares Outstanding for Q4 2025 was $61.3 million at Twist Bioscience, up from $60.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $61.3 million in Q4 2025, with the low at $48.9 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $56.5 million, with a median of $57.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding rose 19.26% in 2021, then increased 1.55% in 2023.
  • Over 5 years, Shares Outstanding stood at $50.7 million in 2021, then increased by 11.65% to $56.6 million in 2022, then increased by 2.0% to $57.8 million in 2023, then increased by 3.12% to $59.6 million in 2024, then increased by 2.84% to $61.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $61.3 million, $60.6 million, and $60.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.